Recent evidence indicates that anti-apoptotic functions of Bcl-2 can be regulated by its phosphorylation. According to the 'mitotic arrest-induced' model, multi-site phosphorylation of the Bcl-2 loop domain is followed by cell death. In contrast, in cytokine-dependent cell lines, cytokines mediate phosphorylation of Bcl-2 on S70, preventing apoptosis. As discussed in this review, these models are not mutually exclusive but reflect different cellular contexts. During mitotic arrest, signal transduction is unique and is fundamentally different from classical mitogenic signaling, since the nucleus membrane is dissolved, gene expression is reduced, and numerous kinases and regulatory proteins are hyperphosphorylated. Hyperphosphorylation of Bcl-2 mediated by paclitaxel and other microtubuleactive drugs is strictly dependent on targeting microtubules that in turn cause mitotic arrest. In addition to serine-70 (S70), microtubule-active agents promote phosphorylation of S87 and threonine-69 (T69), inactivating Bcl-2. A major obstacle for identification of the mitotic Bcl-2 kinase(s) is that inhibition of putative kinase(s) by any means (dominant-negative mutants, antisense oligonucleotides, pharmacological agents) may arrest cycle, preventing mitosis and Bcl-2 phosphorylation. The role of Bcl-2 phosphorylation in cell death is discussed. Leukemia (2001) 15, 869-874.
Introduction
In the last 5 years, an increasing number of publications on Bcl-2 phosphorylation reflects the interest in the regulation of apoptosis. Unlike the p53 protein whose activity is regulated by its expression, the Bcl-2 protein has a long half-life and the regulation by protein expression is limited. 1 In contrast, interactions of Bcl-2 with numerous proteins, including the Bcl-2 family members (eg BclxL, Bax) and kinases play a key role. [2] [3] [4] As with other regulatory proteins (eg Rb and BAD), phosphorylation may be a crucial event in regulation. In 1995, Haldar et al 5 described a shift in the Bcl-2 protein mobility that was consistent with Bcl-2 phosphorylation. 5 An attractive hypothesis of inactivation of Bcl-2 by multi-site phosphorylation became widely accepted, even though this hypothesis was initially based on the correlation. Recently, evidence has emerged to support this hypothesis. 6 There is still controversy over the significance of Bcl-2 phosphorylation and even more over kinases that are responsible for Bcl-2 phosphorylation. Two opposing models of Bcl-2 phosphorylation were initially proposed. According to the 'Taxol-induced' model, Bcl-2 phosphorylation is tightly coupled with hyperphosphorylation of numerous proteins including the Raf-1 kinase but it is independent of protein kinase C (PKC). 7 Neither inhibitors nor activators of PKC affect Bcl-2 phosphorylation. 7 This model implied that phosphorylation inhibits the anti-apoptotic function of Bcl-2. Indepen- dently, by utilizing interleukin-3 (IL-3)-dependent hematopoietic cell lines, Bcl-2 phosphorylation involving PKC had been described. 8 According to the 'IL-3-induced' model, phosphorylation of Bcl-2 increased its anti-apoptotic function. 9 As I will discuss, both phenomena are not mutually exclusive but reflect functioning Bcl-2 in a very different cellular context.
Taxol-induced Bcl-2 phosphorylation is of special interest to oncologists. Like other microtubule-active drugs including the Vinca alkaloids, paclitaxel (Taxol) inhibits microtubule dynamics leading to mitotic arrest. 10 Due to its superior effectiveness in the treatment of metastatic breast and ovarian cancer, paclitaxel achieved the status of a 'wonder-drug'. It was therefore anticipated that, in addition to microtubules, Taxol might have other intercellular targets. Yet, this expectation was not fulfilled. Although paclitaxel can also bind to the loop of Bcl-2 protein, 11 its significance is unclear. Bcl-2 phosphorylation is induced by any microtubule-active drug. 12 Furthermore, Bcl-2 phosphorylation is strictly dependent on the interaction of these drugs with tubulin: thus, paclitaxel did not induce Bcl-2 phosphorylation in cells with mutant tubulin proteins that lack paclitaxel-binding sites. 12 In contrast, other microtubule-active drugs normally induced Bcl-2 phosphorylation in these cells. 12 Microtubule dysfunction during mitosis may result in abnormal chromosome segregation. In analogy with p53 which functions as a guardian of DNA integrity, it has been proposed that Bcl-2 is a guardian of the fidelity of chromosome segregation. 12, 13 Further, Bcl-2 phosphorylation is observed not only in drug-induced mitotic arrest but in normal mitosis. 14, 15 At that point, a precise identification of the site of Bcl-2 phosphorylation became increasingly important, that spotlight the loop domain of Bcl-2, which turned out to be the site of Bcl-2 phosphorylation. 
Bcl-2: function, structure, phosphorylation
According to the most recent definitions, apoptosis is cell death associated with activation of caspases that distinguish apoptosis from other forms of cell death. [17] [18] [19] [20] Caspase cascades are initiated by the activation of either caspase-8 (by death receptors), caspase-12 (the endoplasmic pathway), or caspase-9 (the mitochondrial pathway). The activation of caspase-9 via the mitochondrial pathway depends on cytochrome C release and it is regulated in part by Bcl-2 and related proteins. 21, 22 The founding member of an expanding family of anti-and pro-apototic proteins, Bcl-2 is located in mitochondrial, endoplasmic and nuclear membranes. 23 Bcl-2 blocks cytochrome C release from the mitochondria preventing the activation of caspase-9. 4 On the other hand, paclitaxel causes cytochrome C release and caspase-9 activation that can be blocked by overexpression of both Bcl-2 and BclxL. [24] [25] [26] Bcl-2 possesses a membrane insertion domain (TM), three Figure  1 ). It has been demonstrated that deletion of 32-80 residues within this loop prevent phosphorylation of Bcl-2. 16, 29 First, it was demonstrated that serine 70 (S70) was phosphorylated in both 'Taxol-induced' and 'IL-3-induced' phosphorylation models. 9, 30 In addition to serine-70 (S70), microtubule-active agents also phosphorylated S87 and threonine-69 (T69), causing the appearance of three bands on the Bcl-2 immunoblot. 6 More often, however, for either technical reasons or due to the absence of monophosphorylated Bcl-2, only one or two hyperphosphorylated bands could be detected. In some conditions, Bcl-2 hyperphosphorylation could be manifested by an apparent decrease in total Bcl-2 levels (discussed in Ref. 31 ). Normally, Bcl-2 binds and inactivates Bax, a pro-apoptotic protein. The ability of phosphorylated Bcl-2 to bind Bax remains unclear. Some studies have demonstrated that phosphorylated Bcl-2 lost its capacity to heterodimerize with Bax, 9, 32 other investigations have found that phosphorylated Bcl-2 remained complexed with Bax.
14 Unlike paclitaxel, IL-3 does not induce a change in the mobility of Bcl-2 protein, despite its phosphorylation on S70. Since phosphorylation on S70 by paclitaxel already caused a mobility shift, either it is accompanied by an additional phosphorylation event outside the loop domain or 'IL-3-phosphorylated' Bcl-2 is not visible on immunoblots. The latter possibility is supported by recent findings by Poommipanit et al. 32 Although a majority of Bcl-2 reside in mitochondria, IL-3-induced phosphorylation only affected a minor pool of soluble Bcl-2. 32 A small amount of cytosolic Bcl-2 may not be visible on immunoblot. In contrast, paclitaxel caused phosphorylation of a membrane-bound Bcl-2.
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Effects of deletion of loop domain and point mutations
Bcl-2 lacking the loop domain (Bcl-2⌬32-80) mutant have been constructed to determine the role of this region in Bcl-2 function. However, the deletion of this region has yielded conflicting results with regards to paclitaxel-induced apoptosis. The loop domain was necessary for the anti-apoptotic effects of Bcl-2 against paclitaxel-induced apoptosis in HL-60 cells. 29 In contrast, U937 cells expressing the loop domain mutant (Bcl-2⌬32-80) were significantly more resistant than those overexpressing full-length Bcl-2 with regards to loss of mitochondrial membrane potential, cytochrome c
Figure 1
Sites of phosphorylation of Bcl-2 by paclitaxel and cytokines.
release, caspase-9 and -3 activation, PARP degradation, and cell death mediated by paclitaxel. 33 These discrepancies could be the result of clonal variations, but there are other possible explanations. HL-60 and U937 cells differ in the expression of endogenous Bcl-2 family members which might affect the outcome.
Deletion of another region of the loop domain (residues 51-85) confers a novel gain of function that not only suppresses apoptosis induced by p53 but also permits continued cell proliferation. 34 Nevertheless, interpretation of the deletion of Bcl-2 loop domain studies are difficult. Does the deletion of Bcl-2 loop domain imitate aphosphorylated or a dephosphorylated state of Bcl-2? The answer is not obvious. Therefore, the effects of serine and threonine substitutions in this region by alanine were examined. Changing S70, S87, and T69 to alanine conferred more anti-apoptotic activity to Bcl-2 following physiologic death signals as well as treatment with paclitaxel, indicating that phosphorylation is inactivating. 6 This conclusion was further confirmed in several different models.
Bcl-2 is a substrate for v-cyclin-CDK6 encoded by Kaposi's sarcoma herpesvirus that induces apoptosis in cells with high levels of CDK6. Whereas herpesvirus-encoded v-Bcl-2 protects against this apoptosis, cellular Bcl-2 has lost its antiapoptotic potential as a result of an inactivating phosphorylation in its loop region. Furthermore, a mutant Bcl-2 with a S-70A and S-87A double substitution is not phosphorylated and provides resistance to apoptosis, indicating that inactivation of endogenous cellular Bcl-2 by v-cyclin-CDK6 is required for apoptosis. 35 Insulin receptor substrate (IRS) proteins are docking proteins that couple growth factor receptors to various effector molecules including Bcl-2. IRS-1 associates with the loop domain and upregulates the anti-apoptotic activities of Bcl-2. IRS-1 suppresses phosphorylation of Bcl-2 and the hypophosphorylation may lead to its enhanced anti-apoptotic activity. 36 
'Hyperphosphorylated state' of mitotic arrest
At the end of G2 phase, Cdc2 kinase associated with cyclin B phosphorylates laminin, causing breakage of the nuclear membrane, other key proteins and kinases, initiating mitosis. 37 Mitosis is associated with inhibition of serine/threonine protein phosphatase 2A, PP2A. 38, 39 Furthermore, a mere inhibition of PP2A by okadaic acid induces mitotic-like microtubule dynamic, arrests cells in mitosis 40 and is associated with phosphorylation of Bcl-2.
5,41 Both activation of kinases and inhibition of phosphatases observed in cells treated with microtubule-active drugs causes multiple serine phosphorylations of many regulatory and structural proteins (reviewed in Ref. 42 ). These phosphorylation events radically alter cellular functions. A cell arrested in mitosis lives in a hyperphosphorylated state with nuclear and endoplasmic reticulum dissolved and gene expression shut down.
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Mitotic pathways are distinct from classical pathways
Compared to an interphase cell, signal transduction is unique and fundamentally different in a mitotic cell. An interphase cell monitors external signals that are directed from the cellular membrane to the nucleus modulating gene expression and cell cycle. Instead, a mitotic cell monitors functioning of microtubules and segregation of chromosomes. In mitotic cells, the nucleus does not exist and transcription is reduced 871 or absent. 43 Assembly and functioning of the mitotic spindle is dependent on serine phosphorylation. 38, [44] [45] [46] For example, in interphase cells, Raf-1 is activated by PKC and/or Ras on the cellular membrane, and then transduces its signal to mitogen-activated pathway (see Ref. 47) . In a mitotic cell, although Raf-1 undergoes hyperphosphorylation on multiple serines leading to its enzymatic activation, [48] [49] [50] it does not signal via the MEK/ERK pathway. 31, 49, 51 Moreover, activity of Raf-1 toward MEK may be reduced. 52 Even in an interphase cell, uncoupling Raf-1 from MEK1/2 impairs only a subset of cellular responses, whereas activation of NF-kappaB was unimpaired. 53 In a mitotic cell, Raf-1 has a cytoplasmic (not the cellular membrane) location and its activation is independent of PKC and Ras.
7,51 C-mos (a serine/threonine kinase that is crucial for meiosis) accumulates in mitosis and mitotic arrest. 54, 55 It has been shown that c-mos overexpression alone causes mitotic arrest and cell death. 56 In meiosis, Raf-1 and JNK are downstream of c-Mos. 57, 58 Further study will clarify exact relationships between cdc2/p34, c-mos, ERK, Raf-1, and JNK in mitotic cells. Also, p38 and numerous other kinases are activated during mitotic arrest (reviewed in Ref. 42 ).
What kinase phosphorylates Bcl-2 in mitotic arrest?
Since Bcl-2 is phosphorylated on serine/threonine residues, the mitotic Bcl-2 kinase(s) must be a serine/threonine kinase(s). Mitosis is initiated by the Cdc2 kinase/cyclin B complex, and Cdc2 would be one of the prime suspects. It has been shown that Cdc2 can phosphorylate T56, one of the consensus sites for Cdc2 within the Bcl-2 sequence. 41 In contrast, several studies demonstrated that Cdc2 did not phosphorylate Bcl-2 and did not form complexes with Bcl-2.
6,14 Furthermore, T56 was not identified as a site of phosphorylation caused by paclitaxel. 6 Collectively, these data do not support involvement of Cdc2 in Bcl-2 phosphorylation. Given accumulation of c-Mos in mitosis, 55 I would speculate it might be a Bcl-2 kinase, but no direct evidence is available.
While ERK has been implicated in 'IL-3-induced' Bcl-2 phosphorylation, 59 it is dispensable for Bcl-2 phosphorylation. 31, 60, 61 Depending on the cell line, ERK was found to be activated, unchanged, or even inhibited. Moreover, neither inhibition nor activation of this pathway affected Bcl-2 phosphorylation. 31, [60] [61] [62] (Note: this should not be confused with a strategy designed to inhibit mitogen-activated pathways in order to arrest growth prior to treatment with paclitaxel, thus protecting against all paclitaxel effects.) 63 Inhibition of PKC or MEK during mitotic arrest did not affect or even increase cell sensitivity to paclitaxel. 31, 60, 61, 64, 65 During mitotic arrest a classical Ras/Raf-1/MEK/MAPK signaling pathway does not exist. Mitotic Raf-1 is not activated by Ras and does not phosphorylate MEK. Geldanamycin (GA), which depletes Raf-1, abrogated Bcl-2 phosphorylation. 7, 50, 66 Yet, GA depleted other proteins as well. 67 Most importantly, depletion of Raf-1 and other kinases inhibited cell proliferation, thus precluding mitotic arrest caused by microtubule-active drugs. Hyperphosphorylation of both Raf-1 and Bcl-2 occurs in mitosis and therefore were closely associated. By preventing mitotic arrest, GA may block Bcl-2 phosphorylation, making the results inconclusive. In contrast to other cell lines, HL-60 cells still undergo mitotic arrest in the presence of GA (a personal observation), and GA does not abrogate Bcl-2 phosphorylation in this particular cell line. 25 This highlights the problem with any kinases implicated in Bcl-2 phosphorylation. Inhibition of such kinases by any Leukemia means (dn mutants, antisence, pharmacological inhibition) may cause cell cycle arrest thus preventing mitosis and Bcl-2 phosphorylation.
JNK was repeatedly indicated as a potential Bcl-2 kinase. JNK has been shown to phosphorylate Bcl-2 at four serine/threonine sites (T56, S70, T74, S87). 68 JNK activation occurs immediately after paclitaxel treatment, 69 whereas Bcl-2 phosphorylation is detected after several hours, associated with accumulation of mitotically arrested cells. Therefore, activation of JNK alone is not sufficient for Bcl-2 phosphorylation. However, it does not exclude that JNK is responsible for Bcl-2 phosphorylation in mitotic arrest when phosphatases are inhibited and/or Bcl-2 accessibility become available. Combination of antisense oligonucleotides to JNK1 and JNK2 inhibited vinblastine-induced phosphorylation of Bcl-2 and Bcl-xL. 52 ASK1 and JNK1, that are activated in mitosis phosphorylated Bcl-2 in vitro, and expression of the combination of dominant negative ASK1, (dnASK1), dnMKK7, and dnJNK1 inhibited paclitaxel-induced BCL-2 phosphorylation. 6 In contrast, a slightly different combination (namely, dnSEK1 instead of dnMKK7) could not block Bcl-2 phosphorylation. 70 Also, it has been shown that Cdc42/PAK1 can activate JNK1-induced phosphorylation of Bcl-2. 71 Since a phosphorylation-resistant mutant Bcl-2 (S70, 87A, T56, 74A) gains the ability to inhibit Cdc42-mediated apoptosis, this phosphorylation was inactivating. 71 Unexpectedly, this study suggests the involvement of p53 in Bcl-2 phosphorylation, even though in all other studies Bcl-2 phosphorylation occurs regardless of the p53 status. Furthermore, DNA damaging agents, which induce p53, do not lead to Bcl-2 phosphorylation.
Overall, JNK seems to be one of the strongest candidates for the Bcl-2 kinase. Yet, several kinases may be involved and each of them may be redundant. Based on the sequences around phosphorylated sites, direct phosphorylations of Bcl-2 by PKC and c-AMP kinase are unlikely (see Ref. 52) . Furthermore, these kinases along with p38 and MEK/MAPK were significantly excluded as paclitaxel-activated Bcl-2 kinases. 6, 31, 60, 61 As emphasized, the phosphorylation status of a protein is determined by kinases and phosphatases, and the phosphatases are inhibited during mitotic arrest. This inhibition will result in increased phosphorylated status of proteins, even if the activity of kinases is not increased. I suggest that the Bcl-2 kinase is not necessarily activated (and may be even inhibited) during mitotic arrest but, nevertheless, can be responsible for Bcl-2 phosphorylation.
'IL-3-induced' mitogen-activated model
In IL-3-dependent cell lines, IL-3 and PKC activators suppressed apoptosis and stimulated phosphorylation of Bcl-2. The Bcl-2 mutant (S-70A) was not phosphorylated after IL-3 or bryostatin treatment and was unable to support prolonged cell survival. 9 In contrast, a serine to glutamine mutant, S-70E, which may mimic a potential phosphate charge, more potently suppressed apoptosis than Bcl-2. A nonpeptide activator of cellular MEK/mitogen-activated protein kinase (MAPK) kinase can induce S70 phosphorylation of Bcl-2 and support survival of cells expressing wild-type but not the phosphorylation-incompetent S-70A Bcl-2. In this cell model, the combination of PD98059 and staurosporine completely blocked phosphorylation of Bcl-2. 59 It has been shown that extracellular signal-regulated kinases (ERK)/MAPK are activated by IL-3, colocalize with mito-Leukemia chondrial Bcl-2, and can directly phosphorylate Bcl-2 on S70 in a staurosporine-resistant manner both in vitro and in vivo. These findings suggest a role for the ERK/MAPK kinases. Thus, ERK/MAPK can serve to functionally link the IL-3-stimulated proliferative and survival signaling pathways. 59 A recent publication by Poommipanit et al 32 provides data for modification of the IL-3 model, demonstrating that free rather than mitochondrial Bcl-2 is phosphorylated. According to this study, IL-3-induced phosphorylation of a cytosolic pool of Bcl-2 may contribute to the inactivation of its antiproliferative function. 32 In mitogen-dependent hemopoietic cell lines, Bcl-2 overexpression is synergistic with MEK1 and Raf-1 activities on relieving the cytokine dependency. 47, 72, 73 This suggests that phosphorylation of Bcl-2 promotes mitogen-induced cell survival and proliferation.
In fact, the 'IL-3-induced' model of Bcl-2 phosphorylation mimics phosphorylation of BAD by mitogens. [74] [75] [76] Mitogenactivated phosphorylation of cytoplasmic fractions of Bcl-2 and BAD promote cell survival.
Bcl-2, Bcl-xL, Mcl-1
Like Bcl-2, the anti-apoptotic Bcl-xL and Mcl-1 proteins also undergo hyperphosphorylation after cell exposure to microtubule-active drugs. 66, 77 As with Bcl-2, phosphorylation of BclxL and Mcl-1 occurs on the loop domains. Deletion of the loop domain in Bcl-xL increases its anti-apoptotic function. 16 PKC induces ERK-dependent phosphorylation of Mcl-1 without changing its electrophoretic mobility. In contrast, ERKindependent phosphorylation with mobility shift is caused by mitotic arrest or by inhibitors of PP1/2A. 77 Finally, phosphorylation of Bcl-2 has been demonstrated following treatment with retinoic acid and medroxyprogesterone. 78, 79 
Conclusions and questions
During mitosis and mitotic arrest, inhibition of serine/ threonine phosphatases and activation of serine/threonine kinases result in phosphorylation of numerous proteins including Bcl-2, Bcl-xL and Mcl-1. Multi-site phosphorylation of Bcl-2 inhibits its anti-apoptotic function. Is phosphorylation Bcl-2 different in normal mitosis and in mitotic arrest? Phosphorylation of S87 and T69, in addition to S70, is well established during mitotic arrest. In mitosis, phosphorylation of T69 and S87 has not yet been detected. Alternatively, duration of Bcl-2 phosphorylation, rather than the particular phosphorylation sites, plays the key role in distinguishing normal mitosis and mitotic arrest. The same event can signal cell death or cell proliferation in different cellular contexts. 80 In fact, May and colleagues 8 demonstrate that mitogen-induced phosphorylation of S70 in the Bcl-2 loop domain prevents apoptosis in cytokine-dependent cells.
What is the physiological role of 'mitotic arrest-induced' Bcl-2 phosphorylation. It has been proposed to be monitoring of the fidelity of chromosome segregation. 6, 12, 13 However, the precise physiological scenario Bcl-2 phosphorylation caused by prolonged mitotic arrest is not very clear. I speculate that a more physiological relevant situation is related to meiosis rather than to mitosis. In fact, prolonged arrest in meiosis is an important physiological event in both female oocytes and male germ cells. The majority of ovarian germ cells undergo apoptosis during the meiotic process. 81 Failure of meiosis is coincident with a dramatic increase in spermatocyte apoptosis. 82 Does Bcl-2 phosphorylation play a role in these processes?
What is the role of phosphorylated Bcl-2 with different subcellular locations? Clearly, phosphorylation of Bcl-2 in the nuclear membrane (dissolved during mitotic arrest) and in the mitochondrial membrane may have different functional outcomes.
Multiple serine phosphorylated forms of Bcl-2 are widely distributed in human tissues 83 but the significance is not clear. Upon analyzing the roles of Bcl-2 phosphorylation, it should be kept in mind that Bcl-2 does not affect cell death in many cell types and lines. Indeed, according to the current point of view, Bcl-2 prevents cytochrome C release and mitochondriadependent apoptosis. Although cytochrome C microinjection is sufficient to activate caspases, it does not induce the caspase cascade in apoptosis-resistant cell lines. 84, 85 Perhaps the majority of cell types and lines undergo caspase-independent slow cell death following treatment with drugs including microtubule-active drugs. 19 Bcl-2 has the most significant impact in leukemias and lymphomas and other apoptosisprone tumors. Furthermore, while overexpression of Bcl-2 produces multidrug resistance when assessed in primary lymphomas in vivo, this effect was dramatically reduced when the primary lymphomas were subjected to long-term culture, and was completely missing in the standard clonogenic survival assay. 86 Therefore, I suggest that Bcl-2 phosphorylation cannot accelerate cell death in apoptosis-resistant cell lines. However, this phosphorylation may be a postmark of apoptotic events that occur in apoptosis-prone cells. Recently, small molecular compounds that bind the BH3 domain of Bcl-2-related proteins were identified. 87, 88 Further studies will finally 'unwind' the mysteries of Bcl-2 phosphorylation.
